ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone972-4959-0123
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.55 million
Profitability
Miscellaneous
Employees58
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Rewalk Robotics (NASDAQ:RWLK) Frequently Asked Questions
What is Rewalk Robotics' stock symbol?
Rewalk Robotics trades on the NASDAQ under the ticker symbol "RWLK."
How were Rewalk Robotics' earnings last quarter?
Rewalk Robotics Ltd (NASDAQ:RWLK) issued its earnings results on Thursday, August, 8th. The medical device company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.39. The medical device company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $2.48 million. Rewalk Robotics had a negative return on equity of 452.23% and a negative net margin of 320.80%. View Rewalk Robotics' Earnings History.
When is Rewalk Robotics' next earnings date?
What price target have analysts set for RWLK?
2 equities research analysts have issued 12-month price objectives for Rewalk Robotics' shares. Their predictions range from $2.00 to $9.00. On average, they anticipate Rewalk Robotics' stock price to reach $5.50 in the next year. This suggests a possible upside of 74.1% from the stock's current price. View Analyst Price Targets for Rewalk Robotics.
What is the consensus analysts' recommendation for Rewalk Robotics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rewalk Robotics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rewalk Robotics.
Has Rewalk Robotics been receiving favorable news coverage?
News articles about RWLK stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rewalk Robotics earned a news impact score of -2.3 on InfoTrie's scale. They also gave media stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Rewalk Robotics.
Who are some of Rewalk Robotics' key competitors?
What other stocks do shareholders of Rewalk Robotics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Rewalk Robotics investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Novocure (NVCR), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG) and Park Sterling (PSTB).
Who are Rewalk Robotics' key executives?
Rewalk Robotics' management team includes the folowing people:
- Mr. Lawrence J. Jasinski, CEO & Director (Age 62)
- Mr. Ori Gon, Chief Financial Officer (Age 38)
- Ms. Miri Pariente, VP of QA & Operations (Age 42)
- Mr. Loren Wass, VP of Sales & Reimbursement
- Mr. Andy Dolan, VP of Marketing
Who are Rewalk Robotics' major shareholders?
Rewalk Robotics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Advisor Group Inc. (1.99%), FNY Investment Advisers LLC (1.66%) and Gabelli Funds LLC (0.60%). Company insiders that own Rewalk Robotics stock include Jodi Gricci, Lawrence J Jasinski and Ofir Koren. View Institutional Ownership Trends for Rewalk Robotics.
Which major investors are selling Rewalk Robotics stock?
RWLK stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Inc.. Company insiders that have sold Rewalk Robotics company stock in the last year include Lawrence J Jasinski and Ofir Koren. View Insider Buying and Selling for Rewalk Robotics.
Which major investors are buying Rewalk Robotics stock?
How do I buy shares of Rewalk Robotics?
Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rewalk Robotics' stock price today?
One share of RWLK stock can currently be purchased for approximately $3.16.
How big of a company is Rewalk Robotics?
Rewalk Robotics has a market capitalization of $23.04 million and generates $6.55 million in revenue each year. The medical device company earns $-21,670,000.00 in net income (profit) each year or ($14.75) on an earnings per share basis. Rewalk Robotics employs 58 workers across the globe.View Additional Information About Rewalk Robotics.
What is Rewalk Robotics' official website?
How can I contact Rewalk Robotics?
Rewalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123 or via email at [email protected]
MarketBeat Community Rating for Rewalk Robotics (NASDAQ RWLK)
MarketBeat's community ratings are surveys of what our community members think about Rewalk Robotics and other stocks. Vote "Outperform" if you believe RWLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RWLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
